Evidence map›Paper›PMID 25158102›Full record

ArticleStem cell research & therapy2014

The mesenchymal stromal cell magic bullet finds yet another target.

Claire Masterson, Daniel O'Toole

Abstract readComment
In one paragraph

Article in Stem cell research & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Stem cell-based therapy for human diseases.Signal transduction and targeted therapy · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Claire Masterson
Daniel O'Toole

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rojas and colleagues have presented an exciting paper demonstrating yet another relevant preclinical setting in which the mesenchymal stromal cell has a potential therapeutic application. What is particularly interesting about this study is that it addresses a disease, blood-borne systemic sepsis, which has multiple complex host responses and involves a variety of disparate organs and immune cell types. Here, the authors focus on how this injury relates more specifically to the lung, with quite dramatic improvements in several assessed injury parameters. Where does this latest demonstration of mesenchymal stromal cell efficacy leave us with regard to getting these cell therapies to the acute respiratory distress syndrome patient?

Indexed as

Adult Stem CellsAnimalsBone Marrow CellsBone Marrow TransplantationHumansRespiratory Distress SyndromeStem Cell Transplantation

Identifiers

PMID25158102
PMCPMC4097829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.